Patent ID: 8084210

Claim:
A method comprising: a) analyzing a sample from a subject with a SNP detection assay to determine that said subject is homozygous for the −806C/T polymorphism in the CYP2C19 gene (CYP2C19*17), thereby generating a homozygous CYP2C19*17 genetic analysis result; b) inputting said homozygous CYP2C19*17 genetic analysis result into a system, wherein said system comprises: i) a computer processor for receiving, processing, and communicating data, ii) a storage component for storing data which contains a reference genetic database of results of at least one genetic analysis of CYP2C19*17 homozygosity with respect to response to clopidogrel, and iii) a computer program, embedded within said computer processor, which is configured to process said homozygous CYP2C19*17 genetic analysis result in the context of said reference database to determine, as an outcome, that said subject is an ultrametabolizer of said clopidogrel; c) processing said homozygous CYP2C19*17 genetic analysis result with said computer program in the context of said reference database to determine, as an outcome, that said subject is an ultrametabolizer of said clopidogrel; d) communicating said outcome from said computer program; and e) administering to said subject decreased loading and/or maintenance dosages of said clopidogrel compared to CYP2C19 wild-type dosage levels.